NGNE
Neurogene Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website neurogene.com
- Employees(FY) 82
- ISIN US64135M1053
Performance
+0.3%
1W
-5.37%
1M
+13.07%
3M
+153.12%
6M
+71.88%
YTD
+91.46%
1Y
Profile
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Technical Analysis of NGNE 2024-05-10
Overview:
In analyzing the technical indicators for NGNE over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for informed deci...
Recent News & Updates
- 2024-05-10 01:54
NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024(Investorplace)
- 2024-05-09 19:30
- 2024-05-09 19:30
- 2024-05-06 18:19
- 2024-04-22 16:36
- 2024-04-22 04:36
- 2024-03-20 05:31
- 2024-03-19 06:48
- 2024-03-18 16:14
- 2024-03-18 04:14
- 2024-03-04 07:30
- 2024-03-03 18:30
- 2024-02-29 07:30
Neurogene to Participate in Upcoming Investor Conferences(Business Wire)
- 2024-02-28 18:30
- 2024-01-16 07:00
- 2024-01-15 18:00
- 2024-01-05 07:00
Neurogene Announces Business Update and 2024 Outlook(Business Wire)
- 2024-01-04 18:00
Neurogene Announces Business Update and 2024 Outlook(Businesswire)
- 2023-12-19 07:00
- 2023-12-18 18:00
Page 1 of 1
previousnext